急性対慢性肝不全:北京,中国の臨床結果の比較分析
Hebing Guo1, Ningning Yin1, Jingyuan Liu2
1Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Chaoyang District, Beijing, 100015, China.
BMC gastroenterology
|September 2, 2025
まとめ
急性肝不全 (ALF) と急性慢性肝不全 (ACLF) の患者はしばしば多臓器機能障害症候群 (MODS) を発症する. ALF患者は,ACLF患者と比較して,より高いMODS発生率と,より低い90日生存率に直面しています.
科学分野:
- ヘパトロジー
- クリティカル ケア 医療
- 内科 医学
背景:
- 急性肝不全 (ALF) と急性- 慢性肝不全 (ACLF) は,高い死亡率に関連する重大な疾患である.
- これらの症候群はしばしば多臓器機能不全症候群 (MODS) を引き起こし,患者の末期を複雑にします.
- これらの患者集団におけるMODS発症と死亡率の要因を理解することは,予後を改善するために極めて重要です.
研究 の 目的:
- 中国におけるALFとACLFの患者におけるMODSのアウトカムを調査する.
- これらの肝不全コホートにおける死亡率と予後に影響を与える重要な要因を特定する.
- ALFとACLFの患者のMODSの発生率と生存率を比較する.
主な方法:
- 2009年6月から2022年5月までの585人の患者 (195人のALF,390人のACLF) の遡及コホート分析.
- 北京の専門病院から収集したデータです.
- 統計的分析には,多変数ロジスティック回帰とKaplan- Meier生存分析が含まれていた.
主要な成果:
- ALF患者の61%とACLF患者の45. 1%がMODSを発症した.
- ALF患者は臓器不全の発生率が高く,重症病のスコアも高かった.
- ALF患者は90日間の死亡率が著しく高かった (33. 8% 対 25. 9%).
結論:
- 肝不全患者の約50%がMODSを発症する.
- ALF患者はMODSを発症する可能性が高くなります.
- ALF患者は,ACLF患者と比較して90日間の予後が悪い.
関連する概念動画
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...